MK-2060
MK-2060 is an experimental monoclonal antibody and factor XI inhibitor in development as an antithrombosis agent.[1][2][3]
References
[edit]- ^ Prakash, Swathi; Mares, Adriana C; Porres-Aguilar, Mateo; Mukherjee, Debabrata; Barnes, Geoffrey D (2023). "Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review". Vascular Medicine. doi:10.1177/1358863X231206778.
- ^ Prisco, Domenico; Mattioli, Irene; De Caterina, Raffaele; Bettiol, Alessandra (7 June 2023). "The new era of anticoagulation: factor XI and XII inhibitors". Bleeding, Thrombosis, and Vascular Biology. 2 (2). doi:10.4081/btvb.2023.76.
- ^ De Caterina, Raffaele; Prisco, Domenico; Eikelboom, John W (21 January 2023). "Factor XI inhibitors: cardiovascular perspectives". European Heart Journal. 44 (4): 280–292. doi:10.1093/eurheartj/ehac464.